Research Papers:
IL22 promotes the progression of breast cancer through regulating HOXBAS5
PDF | Full Text | How to cite
Metrics: PDF 2035 views | Full Text 3376 views
Jiang Rui1, Zhao Chunming2, Gao Binbin1, Shao Na1, Wang Shengxi1 and Song Wei1
1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China
2Department of Opthalmology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China
Correspondence to:
Jiang Rui, email: [email protected]
Keywords: IL-22, HOXB-AS5, breast cancer, PI3K/AKT/mTOR
Received: August 01, 2017 Accepted: September 23, 2017 Published: October 19, 2017
ABSTRACT
Interleukin-22 (IL-22) is a well-known tumor related inflammatory factor that is associated with variety of cancers. HOXB-AS5, a long non-coding RNA located in HOX gene clusters, has been elevated in breast cancer (BC) tissues. Herein, IL-22 and HOXB-AS5 were upregulated in the serum and tissues of BC patients and were associated with clinical stages. Furthermore, we also investigated the effects of IL-22-HOXB-AS5 pathway on progression of BC, and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-mTOR pathway. These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.